Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Pharma Equity Group – Opdatering på 1. Kvartal 2024

PEG16.05.2024, 11.00
HC Andersen Capital

Mød og stil spørgsmål til CEO Thomas K. Selsø fra Pharma Equity Group torsdag den 16. maj 2024 kl. 11:00, som vil gennemgå 1. kvartal 2024 samt større begivenheder efter afslutningen af kvartalet.

Pharma Equity Group, har fokus på repositionering af eksisterende API’er (Aktive farmaceutiske ingredienser) til andre indikationer. Pharma Equity Group erhvervede en større portefølje fase 2 projekter i forbindelse med køb af Reponex, indenfor større sygdomsområder. Herunder bakteriel peritonitis (bughindebetændelse), kroniske hudsår, inflammatoriske tarmsygdomme samt tyk- og endetarmskræft. Selskabet arbejder med partnerskabsstruktur for alle sine projekter i fase 3.

Disclaimer: HC Andersen Capital modtager betaling fra Pharma Equity Group for en Digital IR/Corporate Visibility abonnementsaftale. /Claus Thestrup kl. 09.14 17.04.2024.

Upcoming webcasts

Recent videos

Puuilo Q2'26: Piloting in Sweden to begin
10.09.2026, 16.10 Puuilo
HCA Morgenbørs 10/09 - Fokus på fredagens afgørende inflationsrapport
10.09.2026, 10.55 Bang & Olufsen
Sanoma as an Investment | Equity Investors Week Sept. 9, 2026
09.09.2026, 12.30 Sanoma
HCA Morgenbørs 09/09 - Cybersecurity og Palo Alto Networks i fokus i interview med Peter Garnry
09.09.2026, 09.19 FLSmidth & Co.
Rusta, audiocast, Q1'26
09.09.2026, 09.00 Rusta
View all videos